Shobha Kantamneni

Array ( [id] => 17928280 [patent_doc_number] => 20220323405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => COMBINATION PRODUCT USING 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND CARVEDILOL FOR THE TREATMENT OF PSYCHIATRIC DISORDERS [patent_app_type] => utility [patent_app_number] => 17/692094 [patent_app_country] => US [patent_app_date] => 2022-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6510 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17692094 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17655321 [patent_doc_number] => 20220175786 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/677180 [patent_app_country] => US [patent_app_date] => 2022-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17605 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17677180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17828314 [patent_doc_number] => 20220265618 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => METHODS OF TREATING PROSTATE CANCER [patent_app_type] => utility [patent_app_number] => 17/675289 [patent_app_country] => US [patent_app_date] => 2022-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9089 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17675289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18126527 [patent_doc_number] => 20230012148 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-12 [patent_title] => METHODS FOR TREATING PATIENTS WITH HEMATOLOGIC MALIGNANCIES [patent_app_type] => utility [patent_app_number] => 17/675469 [patent_app_country] => US [patent_app_date] => 2022-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19737 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17675469 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17670885 [patent_doc_number] => 20220184052 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => COMPOSITION COMPRISING FEXOFENADINE [patent_app_type] => utility [patent_app_number] => 17/650663 [patent_app_country] => US [patent_app_date] => 2022-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12395 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17650663 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19456738 [patent_doc_number] => 12097206 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-24 [patent_title] => Method for the treatment of Dravet Syndrome [patent_app_type] => utility [patent_app_number] => 17/667136 [patent_app_country] => US [patent_app_date] => 2022-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2828 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17667136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17593468 [patent_doc_number] => 20220143041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => COMBINED THERAPY FOR NMDAR ANTAGONIST-RESPONSIVE NEUROPSYCHIATRIC DISORDERS [patent_app_type] => utility [patent_app_number] => 17/586828 [patent_app_country] => US [patent_app_date] => 2022-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12915 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17586828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19674452 [patent_doc_number] => 12186290 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-07 [patent_title] => Methods for the treatment of glioblastoma multiforme [patent_app_type] => utility [patent_app_number] => 17/587197 [patent_app_country] => US [patent_app_date] => 2022-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 6549 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 169 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17587197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17576820 [patent_doc_number] => 20220133675 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => PHORBOL ESTER COMPOSITIONS AND METHODS OF USE FOR TREATING OR REDUCING THE DURATION OF CYTOPENIA [patent_app_type] => utility [patent_app_number] => 17/577685 [patent_app_country] => US [patent_app_date] => 2022-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15077 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17577685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19032321 [patent_doc_number] => 20240082136 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => TOPICAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/272163 [patent_app_country] => US [patent_app_date] => 2022-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9135 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18272163 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19032321 [patent_doc_number] => 20240082136 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => TOPICAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/272163 [patent_app_country] => US [patent_app_date] => 2022-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9135 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18272163 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19032321 [patent_doc_number] => 20240082136 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => TOPICAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/272163 [patent_app_country] => US [patent_app_date] => 2022-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9135 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18272163 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17702936 [patent_doc_number] => 20220202942 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => BIODEGRADABLE DRUG DELIVERY COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/571804 [patent_app_country] => US [patent_app_date] => 2022-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19951 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17571804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17850486 [patent_doc_number] => 20220280527 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT [patent_app_type] => utility [patent_app_number] => 17/569002 [patent_app_country] => US [patent_app_date] => 2022-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16073 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17569002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17821446 [patent_doc_number] => 11426369 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-30 [patent_title] => Compositions comprising ephedrine or an ephedrine salt and methods of making and using same [patent_app_type] => utility [patent_app_number] => 17/556904 [patent_app_country] => US [patent_app_date] => 2021-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19005 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 188 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17556904 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17821446 [patent_doc_number] => 11426369 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-30 [patent_title] => Compositions comprising ephedrine or an ephedrine salt and methods of making and using same [patent_app_type] => utility [patent_app_number] => 17/556904 [patent_app_country] => US [patent_app_date] => 2021-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19005 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 188 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17556904 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17685780 [patent_doc_number] => 20220193072 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADER [patent_app_type] => utility [patent_app_number] => 17/548842 [patent_app_country] => US [patent_app_date] => 2021-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50980 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17548842 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17670867 [patent_doc_number] => 20220184034 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => METHODS FOR TREATING CUTANEOUS METASTATIC CANCERS [patent_app_type] => utility [patent_app_number] => 17/546715 [patent_app_country] => US [patent_app_date] => 2021-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6804 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17546715 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18860167 [patent_doc_number] => 20230414601 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => INJECTABLE COMPOSITION CONTAINING CASPASE INHIBITOR, AND PREPARATION METHOD THEREFOR [patent_app_type] => utility [patent_app_number] => 18/254696 [patent_app_country] => US [patent_app_date] => 2021-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7193 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18254696 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18860167 [patent_doc_number] => 20230414601 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => INJECTABLE COMPOSITION CONTAINING CASPASE INHIBITOR, AND PREPARATION METHOD THEREFOR [patent_app_type] => utility [patent_app_number] => 18/254696 [patent_app_country] => US [patent_app_date] => 2021-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7193 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18254696 [rel_patent_id] =>[rel_patent_doc_number] =>)